Abstract A017: FAP-Activated Prodrugs Target Cancer Stem Cells in Esophageal Adenocarcinoma
Esophageal adenocarcinoma (EAC) is a rare and lethal malignancy that evolves through a stepwise mucosal progression — from an intestinal metaplasia known as “Barrett's esophagus (BE)” to low-grade dysplasia (LGD), high-grade dysplasia (HGD), and finally invasive carcinoma — each stage harboring rare clonogenic stem c...